Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Stroke. 2007;38:238-240
Published online before print January 4, 2007, doi: 10.1161/01.STR.0000254934.95188.a7
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/2/238    most recent
01.STR.0000254934.95188.a7v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heiss, W.-D.
Right arrow Articles by Sorensen, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heiss, W.-D.
Right arrow Articles by Sorensen, A. G.
Related Collections
Right arrow Imaging
Right arrowRelated Articles

(Stroke. 2007;38:238.)
© 2007 American Heart Association, Inc.

Advances in Stroke 2006

Advances in Imaging 2006

Wolf-Dieter Heiss, MD A. Gregory Sorensen, MD

From the Max Planck Institute for Neurological Research (W.D.H.), Cologne, Germany; and the Massachusetts General Hospital and Harvard Medical School (A.G.S.), Boston, Mass.

Correspondence to A. Gregory Sorensen, MD, Massachusetts General Hospital, 2301 Bldg 149, 13th St, Boston, Mass 02129. E-mail sorensen{at}nmr.mgh.harvard.edu

Imaging in stroke continues to be one of the most dynamic fields of stroke research. Over the past year, researchers have used imaging for acute stroke diagnosis, treatment, and management; to assist in the evaluation of new therapies; to gain insight into neurorecovery, to investigate genetic links; and to better understand animal models of stroke. A full range of imaging technologies are being deployed in the fight against stroke: near-infrared optical, magnetic resonance, positron emission tomography (PET), ultrasound, and x-ray CT are all in active use, aided by both routine and novel tracers and contrast agents. A complete overview of all these advances is not possible in the space allotted here. Hopefully, the sampling of the advances over the past year provided here will convey some of the excitement and activity present in this field.

Imaging is often used to first diagnose both ischemic and hemorrhagic stroke, and advances continue to be made in these areas. The long-standing concept of the ischemic penumbra continues to be confirmed by PET, MRI, and CT. Two multicenter studies published in 2006 demonstrated the potential of imaging to identify candidate patients. In DEDAS,1 the MRI diffusion/perfusion mismatch identified patients in the 3- to 9-hour time window for treatment with the thrombolytic desmoteplase, with apparent benefit especially in patients who fulfilled all MRI criteria. In the DEFUSE study,2 MRI was used successfully to identify both patient subgroups likely to benefit and subgroups unlikely to benefit or possibly to be harmed from treatment in the 3- to 6-hour window. Both of these studies further encourage the notion that treatment might be able to be based not on the clock but rather tailored to an individual patient. Studies with CT methodology are also beginning to support this approach.3,4

Although the general concept of the diffusion-perfusion mismatch as an imaging marker for the ischemic penumbra seems supported, efforts continue to improve delineation of salvageable versus nonsalvageable tissue, versus patients who might be harmed by attempts at thrombolysis, all in hopes of better tailoring treatments to individual patients. This past year has seen substantial advances in these efforts, particularly with MRI and PET techniques. In addition to the clinical studies cited above, the comparison of diffusion/perfusion-weighted imaging (DWI-PWI) to quantitative imaging of flow and oxygen consumption by PET, which "shaped the concept underlying modern acute stroke imaging and remains the gold standard",5 has been applied in several studies for validation of the DWI-PWI mismatch pattern on the PET-derived discrimination of irreversibly damaged, penumbra and hypoperfused tissue—in short, testing this notion not on a patient-level basis, where studies are showing general agreement, but on a voxel-by-voxel basis, where biological and individual heterogeneity is more identifiable. The notion that the DWI lesion contains the finally infarcted tissue with false-positive prediction of up to 25%,6,7 and that the mismatch overestimates the penumbra as defined by increased oxygen extraction fraction and extends into considerable areas with noncritical oligemia,8 was supported by further investigations: whereas the DWI lesion indicates impairment of energy metabolism, the change in apparent diffusion coefficient does not reliably predict tissue outcome,9 and the degree of disturbance in oxygen consumption was variable within individual DWI lesions suggesting variable outcome with potential for recovery.10 In contrast to DWI-PWI, early (<6 hours) hypoattenuation on CT which is related to the severity of ischemia (PET) and the diffusion changes (DWI) both underestimate the penumbra.11

Given these limitations at the tissue level, a number of approaches have been investigated with some success. 11C-flumazenil (FMZ) was shown to be a reliable early marker of preserved neuronal integrity with a correct prediction of 85% of cortical destruction volume and high specificity (negligible false positivity).12 In patients with chronic internal carotid occlusion, selective neuronal damage could be demonstrated by FMZ PET in the hemispheres of patients with border zone infarction beyond the regions of infarcts supporting the hemodynamic origin of these lesions.13 Selective loss of cortical neurons was also shown with iomazenil single-photon emission computed tomography (IMZ-SPECT) in patients with striatocapsular infarctions in transiently hypoperfused cortical tissue which was morphologically intact on MRI.14 These studies suggest that FMZ may prove to be a reliable tracer for neuronal integrity with higher specificity than DWI. The disadvantage—besides requiring PET equipment—is the short half life of the usual carbon-11 label. This can be overcome by using fluorine-18 label, which would allow FMZ to be a widely distributed radiotracer.15

One PET tracer for imaging hypoxia as a surrogate marker of the penumbra is 18F-fluoromisonidazole (FMISO). Binding of this tracer has been shown to occur in a peri-infarct distribution suggesting penumbra tissue, and some of the indicated tissue has been shown to progress to infarction, whereas some is salvaged.16,17 In an experimental study with temporary middle cerebral artery occlusion in rats, the validity of binding of this tracer to hypoxic tissue was documented confirming the value of FMISO for studying cellular hypoxia in ischemic stroke.18

One MRI method for identifying hypoxia is the same BOLD imaging approach used for functional MRI studies. This oxygen-dependent MRI signal change appears to provide a metabolic indicator of tissue at risk in acute stroke patients,19 and may provide a superior means for identification of the penumbra. Additional techniques that are under active development include MRI-based pH imaging20 and microglial activation using PET. Microglial activation indicates the neuroinflammatory response to ischemic stroke and can be visualized by the specific ligand for peripheral benzodiazepine receptor sites 11C-PK11195. Binding of the tracer rises considerably 72 hours after stroke in the core, the peri-infarct zone and even in the contralateral hemisphere suggesting progressing tissue damage.21,22 With the limited effect of available treatment, these delayed pathophysiological mechanisms may represent a therapeutic opportunity for ischemic stroke.

While there is an extensive amount of effort on imaging acute ischemic stroke, imaging has also been highly active in other areas. 2006 saw extensive work looking at the functional impact of stroke and stroke recovery. Crossed cerebellar diaschisis (CCD) has been a functional observation in supratentorial infarction23 and generally is considered a persistent phenomenon even despite clinical recovery. In a study of patients receiving IV thrombolysis,24 it was found that CCD occurs as early as 3 hours after stroke and might be reversible; acute CCD was closely related to the volume of supratentorial hypoperfusion, but at later time points CCD was disconnected from supratentorial perfusion but strongly associated to outcome measures; and CCD was not susceptible to non-nutritional reperfusion. As a consequence, CCD which has not been taken into account during the last few years may add valuable information to interpret supratentorial reperfusion patterns. The altered corticocerebellar circuits responsible for CCD can be visualized by diffusion tensor MRI.25

Stroke recovery has been investigated using MRI methods, with changes in both structure and function identified in human gray matter26,27 and in white matter anectodally and more carefully in animal studies,28 with new MRI methods for quantifying changes in white matter such as diffusion tensor and diffusion spectrum imaging29 showing particular promise. Given the tremendous morbidity from stroke and the challenges to delivery of acute treatment, these areas are particularly important and developments in these areas particularly welcome. New methods for tracking cellular therapies in humans30 hold out promise that imaging may assist chronic recovery strategies.

Finally, imaging is playing a key role in the unraveling of one of the most significant challenges of stroke, that of understanding its genetics. White matter hyperintensities have been known to have a heritable component for some time (with heritability in one twin study was reported at 0.7331). Although our understanding of white matter hyperintensities is incomplete, there does seem to be evidence that white matter hyperintensities, as seen on MRI, are associated with hypertension, stroke, and possibly worse outcome of the penumbra; in 2006 a genome-wide scan demonstrated evidence that a gene on chromosome 4 may influence these white matter hyperintensities.32 The increasing power of imaging to understand and quantify changes in white matter may allow greater insight into the link between stroke and genetics.

Similarly exciting advances have been made in hemorrhagic stroke over the past year, with all diagnostic modalities coming to bear on this illness as well, but space will not allow a full review. Suffice it to say that imaging in stroke remains a fast-moving and innovative area of stroke research.

Disclosures

Neither author has any conflicts of interest to disclose relevant to this article. Dr Sorensen’s relationships are posted at www.biomarkers.org.

Received November 29, 2006; accepted November 30, 2006.

References

  1. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006; 37: 1227–1231.[Abstract/Free Full Text]
  2. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol. 2006; 2560: 508–517.[CrossRef]
  3. Kohrmann M, Juttler E, Fiebach JB, Huttner HB, Siebert S, Schwark C, Ringleb PA, Schellinger PD, Hacke W. MRI versus CT-based thrombolysis treatment within and beyond the 3 hour time window after stroke onset: a cohort study. Lancet Neurol. 2006; 5: 661–667.[CrossRef][Medline] [Order article via Infotrieve]
  4. Wintermark M, Flanders AE, Velthuis B, Meuli R, van LM, Goldsher D, Pineda C, Serena J, van dS, I, Waaijer A, Anderson J, Nesbit G, Gabriely I, Medina V, Quiles A, Pohlman S, Quist M, Schnyder P, Bogousslavsky J, Dillon WP, Pedraza S. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke. 2006; 37: 979–985.[Abstract/Free Full Text]
  5. Muir KW, Buchan A, von KR, Rother J, Baron JC. Imaging of acute stroke. Lancet Neurol. 2006; 5: 755–768.[CrossRef][Medline] [Order article via Infotrieve]
  6. Heiss W-D, Sobesky J, Hesselmann V. Identifying thresholds for penumbra and irreversible tissue damage. Stroke. 2004; 35 (Suppl 1): 2671–2674.[CrossRef][Medline] [Order article via Infotrieve]
  7. Guadagno JV, Warburton EA, Jones PS, Fryer TD, Day DJ, Gillard JH, Carpenter TA, Aigbirhio FI, Price CJ, Baron JC. The diffusion-weighted lesion in acute stroke: heterogeneous patterns of flow/metabolism uncoupling as assessed by quantitative positron emission tomography. Cerebrovasc Dis. 2005; 19: 239–246.[CrossRef][Medline] [Order article via Infotrieve]
  8. Sobesky J, Weber OZ, Lehnhardt FG, Hesselmann V, Neveling M, Jacobs A, Heiss W-D. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke. 2005; 36: 980–985.[Abstract/Free Full Text]
  9. Guadagno JV, Jones PS, Fryer TD, Barret O, Aigbirhio FI, Carpenter TA, Price CJ, Gillard JH, Warburton EA, Baron JC. Local relationships between restricted water diffusion and oxygen consumption in the ischemic human brain. Stroke. 2006; 37: 1741–1748.[Abstract/Free Full Text]
  10. Guadagno JV, Warburton EA, Jones PS, Day DJ, Aigbirhio FI, Fryer TD, Harding S, Price CJ, Green HA, Barret O, Gillard JH, Baron JC. How affected is oxygen metabolism in DWI lesions? A combined acute stroke PET-MR study. Neurology. 2006; 67: 824–829.[Abstract/Free Full Text]
  11. Sobesky J, von KR, Frackowiak M, Weber OZ, Lehnhardt FG, Dohmen C, Neveling M, Moller-Hartmann W, Jacobs AH, Heiss W-D. Early ischemic edema on cerebral computed tomography: its relation to diffusion changes and hypoperfusion within 6 h after human ischemic stroke. a comparison of CT, MRI and PET. Cerebrovasc Dis. 2006; 21: 336–339.[CrossRef][Medline] [Order article via Infotrieve]
  12. Heiss W-D, Sobesky J, Smekal U, Kracht LW, Lehnhardt FG, Thiel A, Jacobs AH, Lackner K. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke. 2004; 35: 1892–1898.[Abstract/Free Full Text]
  13. Yamauchi H, Kudoh T, Kishibe Y, Iwasaki J, Kagawa S. Selective neuronal damage and borderzone infarction in carotid artery occlusive disease: a 11C-flumazenil PET study. J Nucl Med. 2005; 46: 1973–1979.[Abstract/Free Full Text]
  14. Saur D, Buchert R, Knab R, Weiller C, Rother J. Iomazenil-single-photon emission computed tomography reveals selective neuronal loss in magnetic resonance-defined mismatch areas. Stroke. 2006; 37: 2713–2719.[Abstract/Free Full Text]
  15. Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, Vassiliev DA, Gulyas B, Hall H, Savic I, Halldin C. Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol. 2005; 32: 109–116.[CrossRef][Medline] [Order article via Infotrieve]
  16. Read SJ, Hirano T, Abbott DF, Markus R, Sachinidis JI, Tochon-Danguy HJ, Chan JG, Egan GF, Scott AM, Bladin CF, Mckay WJ, Donnan GA. The fate of hypoxic tissue on 18F-fluoromisonidazole PET after ischemic stroke. Ann Neurol. 2000; 48: 228–235.[CrossRef][Medline] [Order article via Infotrieve]
  17. Markus R, Reutens DC, Kazui S, Read S, Wright P, Pearce DC, Tochon-Danguy HJ, Sachinidis JI, Donnan GA. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain. 2004; 127: 1427–1436.[Abstract/Free Full Text]
  18. Spratt NJ, Ackerman U, Tochon-Danguy HJ, Donnan GA, Howells DW. Characterization of fluoromisonidazole binding in stroke. Stroke. 2006; 37: 1862–1867.[Abstract/Free Full Text]
  19. Geisler BS, Brandhoff F, Fiehler J, Saager C, Speck O, Rother J, Zeumer H, Kucinski T. Blood-oxygen-level-dependent MRI allows metabolic description of tissue at risk in acute stroke patients. Stroke. 2006; 37: 1778–1784.[Abstract/Free Full Text]
  20. Jones CK, Schlosser MJ, van Zijl PC, Pomper MG, Golay X, Zhou J. Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med. 2006; 56: 585–592.[CrossRef][Medline] [Order article via Infotrieve]
  21. Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T, Aigbirhio F, Baron JC, Warburton EA. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke. 2006; 37: 1749–1753.[Abstract/Free Full Text]
  22. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005; 24: 591–595.[CrossRef][Medline] [Order article via Infotrieve]
  23. Baron JC, Bousser MG, Comar D, Castaigne P. "Crossed cerebellar diaschisis" in human supratentorial brain infarction. Trans Am Neurol Assoc. 1980; 105: 459–461.
  24. Sobesky J, Thiel A, Ghaemi M, Hilker RH, Rudolf J, Jacobs AH, Herholz K, Heiss W-D. Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab. 2005; 25: 1685–1691.[CrossRef][Medline] [Order article via Infotrieve]
  25. Kim J, Lee SK, Lee JD, Kim YW, Kim DI. Decreased fractional anisotropy of middle cerebellar peduncle in crossed cerebellar diaschisis: diffusion-tensor imaging-positron-emission tomography correlation study. AJNR Am J Neuroradiol. 2005; 26: 2224–2228.[Abstract/Free Full Text]
  26. Cramer SC, Shah R, Juranek J, Crafton KR, Le V. Activity in the peri-infarct rim in relation to recovery from stroke. Stroke. 2006; 37: 111–115.[Abstract/Free Full Text]
  27. Schaechter JD, Moore CI, Connell BD, Rosen BR, Dijkhuizen RM. Structural and functional plasticity in the somatosensory cortex of chronic stroke patients. Brain. 2006; 129: 2722–2733.[Abstract/Free Full Text]
  28. Jiang Q, Zhang ZG, Ding GL, Silver B, Zhang L, Meng H, Lu M, Pourabdillah NDS, Wang L, Savant-Bhonsale S, Li L, Bagher-Ebadian H, Hu J, Arbab AS, Vanguri P, Ewing JR, Ledbetter KA, Chopp M. MRI detects white matter reorganization after neural progenitor cell treatment of stroke. Neuroimage. 2006; 32: 1080–1089.[CrossRef][Medline] [Order article via Infotrieve]
  29. Wedeen VJ, Hagmann P, Tseng WY, Reese TG, Weisskoff RM. Mapping complex tissue architecture with diffusion spectrum magnetic resonance imaging. Magn Reson Med. 2005; 54: 1377–1386.[CrossRef][Medline] [Order article via Infotrieve]
  30. deVries I, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005; 23: 1407–1413.[CrossRef][Medline] [Order article via Infotrieve]
  31. Carmelli D, Decarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998; 29: 1177–1181.[Abstract/Free Full Text]
  32. DeStefano AL, Atwood LD, Massaro JM, Heard-Costa N, Beiser A, Au R, Wolf PA, Decarli C. Genome-wide scan for white matter hyperintensity: the Framingham Heart Study. Stroke. 2006; 37: 77–81.[Abstract/Free Full Text]

Related Articles:

The Thr715Pro Polymorphism of the P-Selectin Gene Is Not Associated With Ischemic Stroke Risk
Julia Ferrari, Sandra Rieger, Georg Endler, Stefan Greisenegger, Marion Funk, Thomas Scholze, Wilfried Lang, Wolfgang Lalouschek, and Christine Mannhalter
Stroke 2007 38: 395-397. [Abstract] [Full Text] [PDF]

Update on the Genetics of Stroke and Cerebrovascular Disease 2006
Martin Dichgans and Robert A. Hegele
Stroke 2007 38: 216-218. [Full Text] [PDF]

Advances in Interventional Neuroradiology 2006
David M. Pelz, Elad I. Levy, and L. Nelson Hopkins
Stroke 2007 38: 232-234. [Full Text] [PDF]

Primary Prevention and Health Services Delivery
Larry B. Goldstein and Peter M. Rothwell
Stroke 2007 38: 222-224. [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/2/238    most recent
01.STR.0000254934.95188.a7v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heiss, W.-D.
Right arrow Articles by Sorensen, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heiss, W.-D.
Right arrow Articles by Sorensen, A. G.
Related Collections
Right arrow Imaging
Right arrowRelated Articles

Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.